治疗前全血 Epstein-Barr 病毒 DNA 可预测霍奇金淋巴瘤的预后。
Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma.
机构信息
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
出版信息
Leuk Res. 2021 Aug;107:106607. doi: 10.1016/j.leukres.2021.106607. Epub 2021 Apr 30.
The study investigated pretreatment Epstein-Barr virus (EBV) DNA status and its prognostic values in 96 patients newly diagnosed Hodgkin lymphoma (HL). With 13.5 % patients in positive EBV DNA status before therapy, the positive group had inferior progression-free survival (PFS) (P = 0.023) as well as overall survival (OS) (P = 0.001). Pretreatment EBV DNA positivity was observed as an independent prognostic factor in OS (P = 0.036) while a trend to predict PFS (P = 0.064). By monitoring changes of EBV DNA copies in 13 patients with positive pretreatment EBV DNA status, 5 of 6 patients with complete response (CR) had their copies undetectable after 3 cycles of first-line treatment and 7 patients with progressive disease (PD) all had elevated EBV DNA copies during their relapsed period. Whole blood EBV DNA may be an adjunctive biomarker to reflect treatment response, risk of disease relapse as well as prognosis in HL patients.
本研究调查了 96 例新诊断霍奇金淋巴瘤（HL）患者治疗前 EBV 病毒（EBV）DNA 状态及其预后价值。在治疗前，有 13.5%的患者 EBV DNA 呈阳性，阳性组患者无进展生存期（PFS）（P=0.023）和总生存期（OS）（P=0.001）更差。治疗前 EBV DNA 阳性是 OS 的独立预后因素（P=0.036），但对 PFS 的预测有一定趋势（P=0.064）。通过监测 13 例治疗前 EBV DNA 阳性患者的 EBV DNA 拷贝数变化，6 例完全缓解（CR）患者中有 5 例在一线治疗 3 个周期后检测不到拷贝数，7 例进展性疾病（PD）患者在复发期间 EBV DNA 拷贝数均升高。全血 EBV DNA 可能是一种辅助生物标志物，可反映 HL 患者的治疗反应、疾病复发风险和预后。
Zotero 插件